A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Changchun BCHT Biotechnology
  • Most Recent Events

    • 13 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top